Second-Line Treatment for H. pylori Infection After First-Line Failure

Introduction to Second-Line Treatment

The European Society of Gastrointestinal Endoscopy recommends that after failure of a PPI-clarithromycin containing therapy, either a bismuth-containing quadruple therapy or levofloxacin-containing triple therapy is used as second-line treatment for H. pylori infection 1

The American Gastroenterological Association recommends bismuth quadruple therapy (PPI, bismuth salt, tetracycline, and metronidazole) as a second-line treatment option after first-line failure with clarithromycin-based triple therapy 2, 3, 4
The European Helicobacter Study Group recommends levofloxacin-containing triple therapy (PPI, levofloxacin, amoxicillin) for 10 days as a second-line treatment option after first-line failure with bismuth quadruple therapy 4, 5

The American College of Gastroenterology recommends high-dose PPI (twice daily) to increase efficacy of therapy 2, 6
The European Society of Gastrointestinal Endoscopy recommends a treatment duration of 10-14 days for optimal eradication rates 5

The American Gastroenterological Association recommends avoiding levofloxacin in patients with chronic respiratory conditions who may have previously received fluoroquinolones 4
The European Helicobacter Study Group recommends avoiding reusing antibiotics that failed in previous treatment attempts, particularly clarithromycin and levofloxacin, as resistance is common after exposure 5

The American College of Gastroenterology recommends using urea breath test (UBT) or laboratory-based validated monoclonal stool test to confirm eradication at least 4 weeks after completion of therapy 8

The European Society of Gastrointestinal Endoscopy recommends guiding treatment by antimicrobial susceptibility testing whenever possible after failure of second-line therapy 2, 4